Latest news
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 06:05:44 GMTRenaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeatMarketBeat · Fri, 07 Aug 2026 17:49:25 GMTKROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - The Globe and MailThe Globe and Mail · Tue, 04 Aug 2026 15:46:00 GMTH.C. Wainwright Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $20 - MoomooMoomoo · Tue, 04 Aug 2026 13:31:00 GMTKeros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.33, Implies 101% Upside - TradingViewTradingView · Tue, 04 Aug 2026 13:20:05 GMTKeros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - MarketBeatMarketBeat · Tue, 04 Aug 2026 12:18:37 GMTKeros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Tue, 04 Aug 2026 12:00:25 GMTKeros Q2 FY26 net loss narrows to $28.7 million; R&D expenses drop 48.74% to $22.3 million - BitgetBitget · Tue, 04 Aug 2026 02:03:46 GMT